Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Optimizing Esophageal Cancer Treatment: Personalized Ctdna Improves Residual Disease Detection After Neoadjuvant Chemoradiotherapy and Guides Adaptive Adjuvant Immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhichao LiuCLChunguang LiGWGuoqiang Wang

Discussion

Loading...

Member takes

Overview

Observational analysis shows that personalized ctDNA enhances residual disease detection in ESCC, suggesting improved patient selection for adjuvant immunotherapy.

Key Points

  • Personalized ctDNA improved detection rates for residual disease, with a 99.2% detection at baseline.
  • Incorporating ctDNA into diagnostics raised sensitivity for predicting non-pathologically complete response to 92.0%.
  • MRD positivity after ctDNA assessment correlated with worse disease-free survival for the patients studied.
  • Integration of ctDNA may guide adaptive treatment management strategies in locally advanced esophageal cancer.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b8f4https://doi.org/10.1093/dote/doaf061.046
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma2025
  2. 2Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma2025 · 4 citations
  3. 3142. PREDICTIVE ROLE OF CTDNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT IMMUNOTHERAPY AND CHEMOTHERAPY: A PROSPECTIVE COHORT STUDY2025
  4. 4353. PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN THE PERIOPERATIVE MANAGEMENT OF ESOPHAGEAL CANCER2025
  5. 5Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay2025